KYTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KY

Mkt Cap

$351.1M

Volume

644.27K

Next Earnings

November 11th

Loading chart

KY

KYTXKyverna Therapeutics, Inc. Common Stock

KYTX

Pay with—

Available Balance0.00

KY

Mkt Cap

$369.2M

Volume

644.27K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsightThe lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.GlobeNewswire Inc. · Jun 10, 2026

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?The article compares two biotech companies with contrasting profiles: Kyverna Therapeutics, a clinical-stage firm developing cell therapies for autoimmune diseases with no approved products and significant losses, versus Vertex Pharmaceuticals, an established leader generating $12 billion in revenue with a dominant cystic fibrosis franchise. The author recommends Vertex as the better 2026 investment due to its proven profitability, strong cash flow, and continued growth potential, while acknowledging Kyverna's high-risk, high-reward profile dependent on regulatory approval of its lead candidate.The Motley Fool · Jun 8, 2026

Kyverna Therapeutics to Present at Upcoming Investor ConferencesKyverna Therapeutics (KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases, announced upcoming presentations at the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19th and the Jefferies Global Healthcare Conference on June 3rd, 2026. The company is advancing its lead CAR T-cell therapy candidate miv-cel across multiple B-cell-driven autoimmune indications, including stiff person syndrome and generalized myasthenia gravis.GlobeNewswire Inc. · May 14, 2026

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingKyverna Therapeutics announced positive primary analysis results from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel) for stiff person syndrome (SPS). A single dose demonstrated statistically significant improvements across all primary and secondary endpoints at 16 weeks, with 81% of patients achieving clinically meaningful improvement in walking speed and all 26 patients discontinuing chronic immunotherapies. The company plans to submit a BLA for this indication and is advancing the therapy in generalized myasthenia gravis.GlobeNewswire Inc. · Apr 21, 2026

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of DirectorsKyverna Therapeutics announced the appointments of Sravan K. Emany and Andrew Miller to its Board of Directors as the company advances toward commercialization of its cell therapies for autoimmune diseases. Emany, currently CFO of Beam Therapeutics, brings capital markets and rare disease expertise, while Miller, a Time Magazine honoree and former Karuna Therapeutics leader, adds clinical development and product approval experience. Dan Spiegelman has stepped down from the Board.GlobeNewswire Inc. · Feb 24, 2026

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.Benzinga · Dec 31, 2025

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockKyverna Therapeutics, a clinical-stage biopharmaceutical company, has priced a public offering of 13,333,333 shares at $7.50 per share, expecting to raise approximately $100 million to support its cell therapy development for autoimmune diseases.Benzinga · Dec 17, 2025

Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate ClarityU.S. stock markets experienced a slight decline on December 15, 2025, with the S&P 500, Nasdaq, and Dow Jones showing modest losses as investors await economic data and potential Federal Reserve rate decisions.The Motley Fool · Dec 15, 2025

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person SyndromeKyverna Therapeutics will host a conference call to discuss topline results from its Phase 2 clinical trial of KYV-101, a CD19 CAR T-cell therapy targeting stiff person syndrome, with potential for durable disease-free remission.GlobeNewswire Inc. · Dec 14, 2025

Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsightThe diffuse cutaneous systemic sclerosis (dcSSc) market is evolving towards targeted therapies addressing fibrosis and immune modulation, with promising drug candidates from multiple pharmaceutical companies targeting various pathogenic pathways.GlobeNewswire Inc. · Oct 6, 2025

to start trading

KY

KYTXKyverna Therapeutics, Inc. Common Stock

KYTX

Pay with—

Available Balance0.00

Your PositionYou don't own any KYTX yet.

Related Tickers

Earnings